NCT07207369View on ClinicalTrials.gov

A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

395

Participants

Timeline

Start Date

October 16, 2025

Primary Completion Date

November 30, 2029

Study Completion Date

November 30, 2029

Conditions
Acne Scars
Interventions
DEVICE

ELAPR002f Injectable Gel

Intradermal Injections

DEVICE

Saline Control

Intradermal Injections

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY